ArticleCureus2026
Correlation of Serum Intercellular Adhesion Molecule 1 and Transforming Growth Factor Beta 1 With Diabetic Retinopathy in North Indian Patients With Type 2 Diabetes Mellitus.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic retinopathy is a major microvascular complication of diabetes mellitus. Inflammatory and fibrotic pathways, mediated by intercellular adhesion molecule 1 and transforming growth factor beta 1, play crucial roles in its pathogenesis.
objectiveThis study aims to investigate the correlation of serum intercellular adhesion molecule 1 and transforming growth factor beta 1 levels with diabetic retinopathy in patients with type 2 diabetes mellitus.
methodsA hospital-based case-control study was conducted comprising 60 participants, divided into 30 cases with diabetic retinopathy and 30 controls without retinopathy. Fasting blood sugar, postprandial blood sugar, glycated hemoglobin, lipid profile, and renal function parameters were evaluated. Serum intercellular adhesion molecule 1 and transforming growth factor beta 1 levels were measured using enzyme-linked immunosorbent assay. Diabetic retinopathy was graded using the Early Treatment Diabetic Retinopathy Study (ETDRS) classification.
resultsPatients with diabetic retinopathy exhibited significantly higher levels of serum intercellular adhesion molecule 1 (1638.8 ± 839.7 ng/L) and transforming growth factor beta 1 (755.45 ± 237.86 ng/L) compared to controls (315.73 ± 385.80 ng/L and 342.26 ± 138.42 ng/L, respectively) (p < 0.001). Both biomarkers showed significant positive correlations with glycated hemoglobin, fasting blood sugar, postprandial blood sugar, blood urea nitrogen, and serum creatinine. Furthermore, levels of both biomarkers increased progressively with advancing severity of diabetic retinopathy.
conclusionsElevated serum intercellular adhesion molecule 1 and transforming growth factor beta 1 levels are significantly associated with the presence and severity of diabetic retinopathy. These biomarkers may serve as valuable noninvasive indicators of endothelial dysfunction, inflammation, and fibrosis in disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.